We are live on ! Find out more
DAWN icon

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

1 hedge funds and large institutions have $3.55K invested in Day One Biopharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 204 closing their positions.

New
Increased
Maintained
Reduced
Closed

84.1% less ownership

Funds ownership: 84.1% → 0% (-84%)

100% less funds holding

Funds holding: 208 → 1 (-207)

100% less funds holding in top 10

Funds holding in top 10: 5 → 0 (-5)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $1.84B

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 204

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-207
Holders Change %
-99.52%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
204
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$151M
2
Glazer Capital LLC
Glazer Capital LLC
New York
-$100M
3
Fidelity International
Fidelity International
Bermuda
-$88.6M
4
Kryger Capital
Kryger Capital
United Kingdom
-$83.5M
5
Deerfield Management
Deerfield Management
New York
-$79.8M

DAWN Hedge Fund Activity: Q2 2026 in Review

1 of the 8,367 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2026, worth a combined $3.55K — down 100% from $1.85B a quarter earlier.

Sellers outnumbered buyers: 204 funds closed out of DAWN and 0 opened new positions — a net loss of 204 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $151M sold.

  • 1 institutional investor held Day One Biopharmaceuticals (DAWN) as of Q2 2026, down from 208 in Q1 2026.
  • Funds reported $3.55K of Day One Biopharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Day One Biopharmaceuticals positions in Q2 2026 and 204 closed out, a net change of -204 holders.
  • The largest Day One Biopharmaceuticals seller in Q2 2026 was BlackRock, an estimated $151M sold.

Based on aggregated 13F filings for Q2 2026.